

A background image showing several blue and green COVID-19 virus particles against a dark blue gradient.

THE IMPORTANCE OF ORAL HYGIENE FOR INFECTION CONTROL WITH PVP-I GARGLE DURING COVID-19 OUTBREAK

Prof. drg. Rahmi Amtha, MDS, Sp.PM, PhD
Departemen Ilmu Penyakit Mulut
Universitas Trisakti
SATGAS COVID-19 PB PDGI



Pandemik COVID-19 yang disebabkan karena coronavirus SARS-CoV-2 memberikan dampak luas bagi sistem kesehatan nasional, tidak hanya di Indonesia, tapi dunia




WHO mengeluarkan panduan bagi masyarakat untuk mengurangi paparan dan transmisi penyakit/infeksi melalui *personal hygiene* (kebersihan diri) yaitu kebersihan **tangan** dan **saluran pernafasan** serta keamanan pangan

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public>


- Data per tanggal 15 Mei 2020 jumlah pasien mencapai **16.496** dan **1076** meninggal
- CFR 6,5%
- Pasien COVID -19 masih tetap menunjukkan peningkatan jumlah


- Laporan Wang dkk (2020), ditemukan 41% pasien mempunyai transmisi nosokomial dan disimpulkan oleh WHO-CDC bahwa penyebaran COVID-19 melalui droplet atau aerosol.



Saliva mengandung konsentrasi tinggi COVID-19 sebanyak $1,2 \times 10^8$ kopi/mL (To dkk, 2020).

COVID-19: Transmision





Rationale

Viral load terbanyak di **NASOPHARINK** dan **OROPHARINK** dan menjadi reservoir utama penyebaran droplet atau aerosol.¹

Jumlah virus pada pasien OTG, OPD, PDP serupa.¹

1 Leila JM et al, 2020. Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as "Personal Protective Equipment" for frontline providers exposed in high-risk head and neck and skull base oncology care. *Oral Oncology*. <https://doi.org/10.1016/j.oraloncology.2020.104724>.

2. To KK-W, Tsang OT-Y, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2020; 361: 1319.

Rationale

antivirus

Vitamin C

antibiotik

imunomodulator



Tamiflu

Chloroquine

Reservoir virus pada tenggorok dan hidung ???

Protap Covid dilakukan secara sistemik

Terlokalisir belum diintervensi



Gargle benefit - evidence based

Pencegahan infeksi saluran pernapasan atas (ISPA) masih merupakan masalah utama kesehatan masyarakat.¹

Gargle air pada orang sehat menghasilkan penurunan 36% insidensi ISPA.¹

Gargle dengan air keran, teh hijau atau air fungsional menghasilkan penurunan *odds ratio* munculnya demam pada anak-anak.²


Gargle dianggap sebagai suatu cara yang efektif dan tepat untuk menjaga higiene tenggorok dan mencegah demam pada anak.²

Di Jepang, panduan menganjurkan gargle sebagai salah satu cara pencegahan ketika terjadi pandemi influenza.¹

Dari semua antiseptik rongga mulut yang beredar di pasaran, terdapat obat kumur yang sudah lama beredar (>60 tahun) dengan bahan dasar Povidone-Iodine



Efek Broad-Spectrum dari Povidone - Iodine



Referensi :

1. Ripa S, Bruno R, Reder R. Clinical applications of povidone-iodine as a topical antimicrobial. In: Paulson DS, ed. Handbook of Topical Antimicrobials Industrial Applications. CRC Press. 2002.
2. Tan E chua I, Muller S. Comparative Testing of Betadine and other commercially Available Antiseptics, Based on Current European Suspension Assay. Presented at: International Wound&Biotherapy Conference; 16-18 October 2015, Malaysia.


PVP-I: Antimikrobisidal spektrum luas

Gram Negative Bacteria ¹	Gram Positive Bacteria ¹	Fungi ¹	Viruses
<ul style="list-style-type: none">• <i>Acinetobacter</i> sp.• <i>Aerobacter aerogenes</i>• <i>Aeromonas</i> sp.• <i>Bacteroides</i> sp. (<i>oralis</i>)^{1,11}• <i>Burkholderia cepacia</i>• <i>Campylobacter jejuni</i>• <i>Chlamydia trachomatis</i>• <i>Citrobacter</i> sp.• <i>Edwardsiella</i> sp.• <i>Enterobacter aerogenes</i>• <i>Escherichia coli</i>⁵• <i>Haemophilus</i> sp. (<i>vaginalis</i>)^{1,11}• <i>Gardnerella vaginalis</i>• <i>Herellea</i> sp.• <i>Klebsiella pneumoniae</i>• <i>Moraxella catarrhalis</i>¹⁰• <i>Mima polymorpha</i>¹¹• <i>Morganella morganii</i>• <i>Mycoplasma hominis</i>• <i>Neisseria gonorrhoeae</i>• <i>Proteus</i> sp.• <i>Providencia</i> sp.• <i>Pseudomonas</i> sp.• <i>Salmonella</i> sp.• <i>Serratia</i> sp.• <i>Shigella</i> sp.• <i>Ureaplasma urealyticum</i>• <i>Vibrio</i> sp.	<ul style="list-style-type: none">• <i>Bacillus</i> sp.• <i>Clostridium</i> sp.• <i>Corynebacterium</i> sp.• <i>Diphtheroides</i> sp.• <i>Diplococcus pneumoniae</i>¹⁰• <i>Enterococcus</i> sp.• <i>Lactobacillus acidophilus</i>• <i>Micrococcus</i> sp.¹ incl. <i>Micrococcus flavus</i>¹¹• <i>Peptostreptococcus</i>• <i>Sarcina lutea</i>• <i>Staphylococcus</i> sp. incl. methicillin resistant (MRSA), <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>• <i>Streptococcus</i> sp. incl. <i>Streptococcus pneumoniae</i>, <i>Streptococcus faecalis</i>, <i>Streptococcus pyogenes</i>• Vancomycin resistant <i>Enterococcus</i> sp.	<ul style="list-style-type: none">• <i>Aspergillus</i> sp.• <i>Blastomyces dermatitidis</i>• <i>Candida</i> sp.¹ incl. <i>Candida albicans</i>⁵• <i>Cladosporium</i> sp.• <i>Cryptococcus neoformans</i>• <i>Debaryomyces</i> sp.• <i>Epidermophyton floccosum</i>• <i>Microsporum audouinii</i>• <i>Nocardia</i> sp.• <i>Piedraia</i> sp.• <i>Pityrosporum ovale</i>• <i>Streptomyces</i> sp.• <i>Torulopsis glabrata</i>• <i>Trichophyton</i> sp.	<ul style="list-style-type: none">• <i>Adenovirus type 5</i>³• <i>Bovine viral diarrhoea</i>³• Coronaviruses incl. MERS-COV⁷ and SARS-COV⁴• <i>Coxsackievirus A</i>¹⁶⁶• <i>Cytomegalovirus</i>¹• <i>Ebola virus</i>⁶• <i>Enterovirus 71</i>⁸• <i>Herpes simplex virus type 1</i>^{1,2}• <i>Human Immunodeficiency Virus</i>^{1,2}• <i>Influenza A virus</i>⁴• <i>Measles virus</i>²• <i>Mumps virus</i>²• <i>Norovirus</i>⁹• <i>Polyomavirus SV40</i>³• <i>Rabies virus</i>¹• <i>Rhinovirus</i>²• <i>Rotavirus</i>²• <i>Rubella virus</i>¹• <i>Vaccinia virus</i>⁶⁻⁷
	Mycobacteria¹ <ul style="list-style-type: none">• <i>M. chelonae</i>• <i>M. fortuitum</i>• <i>M. tuberculosis</i>	Protozoa & Other Organisms¹ <ul style="list-style-type: none">• <i>Chlamydia trachomatis</i>• <i>Entamoeba histolytica</i>• <i>Mycoplasma hominis</i>• <i>Trichomonas vaginalis</i>• <i>Treponema pallidum</i>	Spores¹ <ul style="list-style-type: none">• Spores of <i>Aspergillus</i> sp.• Spores of <i>Bacillus</i> sp.• Spores of <i>Clostridium</i> sp.• Spores of <i>Penicillium</i> sp.

Perbandingan Aktivitas Beberapa Jenis Antiseptik

Zat Kimia/ Bahan	Bakteri			Virus		Jamur
	Gram +	Gram -	Spora	Lipofilik	Hidrofilik	
Alkohol (Etanol, Isopropanol)	HS	HS	R	S	V	-
Aldehida (Formaldehida, Glutaraldehida)	S	HS	S	S	MS	S
Klorheksidin glukonat	HS	MS	R	V	R	-
Klorin natrium hipoklorit	HS	HS	S	S	S	MS
<i>Hexachlorophene</i>	S	R	R	R	R	R
Iodine (Povidone-Iodine)	HS	HS	S	S	S	S
Fenol	HS	HS	R	R	R	-
Oksidator/ hidrogen peroksida	HS	HS	S	V	V	S
<i>Quaternary ammonium (benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride)</i>	HS	HS	R	S	R	

HS: highly susceptible; MS: moderately susceptible; S: susceptible; R: resistant; V: variable; – no data



PVP-I Versus Infeksi Saluran Nafas

Kanagalingam dkk (2015), PVP-I juga efektif dalam mengurangi keparahan dan mempercepat durasi dari infeksi traktus respiratorius atas seperti *common cold*

Influenza dan tonsilo-faringitis (Ludwig, 2013)

PVP-I pada pasien penyakit kritis yang menggunakan ventilator untuk mencegah timbulnya *ventilator associated pneumonia* (Seguin dkk, 2006).

Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical Reagents

Hiroaki Kariwa^a Nobuhiro Fujii^b Ikuo Takashima^a^aLaboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University, and^bDepartment of Microbiology, School of Medicine, Sapporo Medical University, Sapporo, Japan**Key Words**

Severe acute respiratory syndrome · Coronavirus ·

Povidone-iodine · Infection control

Abstract

The efficacy of several povidone-iodine (PVP-I) products, a number of other chemical agents and various physical conditions were evaluated for their ability to inactivate the severe acute respiratory syndrome coronavirus (SARS-CoV). Treatment of SARS-CoV with PVP-I products for 2 min reduced the virus infectivity from 1.17×10^6 TCID₅₀/ml to below the detectable level. The efficacy

Introduction

Severe acute respiratory syndrome (SARS) was first reported as an atypical pneumonia in Guangdong, China in November 2002 [1]. The epidemic expanded rapidly to 26 regions and countries [2–4], and by the end of June 2003, 8,098 probable cases had been reported and more than 774 people had died [5]. Although the epidemic seemed to be controlled during the summer of 2003, laboratory-associated infections appeared in Singapore in September 2003, in Taiwan in December 2003 and in Beijing in April 2004. At the end of 2003, a new series of probable SARS cases, which may have been unrelated to

Purpose

Nosocomial infections with respiratory tract viruses, particularly influenza and respiratory syncytial virus (RSV), can cause widespread and intractable outbreaks as the recent outbreaks of RSV in a haematology and transplant unit have shown.¹ Reported emerging and re-emerging viral outbreaks with serious implications on public health and nosocomial infections include Severe Acute Respiratory Syndrome (SARS) or Middle East respiratory syndrome (MERS).

Influenza viruses are spread via airborne dispersion of small particle aerosols. MERS, in contrast, seems to require closer contact, with virus passed on hands, fomites, or in large droplets inoculated into the eyes and nose at close range. SARS has two modes of transmission: aerosols of respiratory droplets and from contaminated surfaces, including direct person-to-person contact.

The virucidal efficacy of antiseptics and disinfectants can be determined using the European Standard EN 14476:2013/A1:2014.² Based on these criteria, the antiseptic povidone iodine (PVP-I) has been shown to be effective against the Ebola virus.³

The aim of this study was to investigate the *in-vitro* efficacy of four PVP-I formulations against enveloped


Can oral disinfection with povidone iodine prevent viral respiratory infections?

M. Eggers,¹ M. Eickmann,² J. Zorn³¹Labor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany²Institute for Virology, Philipps University of Marburg, Marburg, Germany³Mundipharma Research GmbH & Co. KG, Limburg, Germany


ASN226


Interfering substance	
Clean conditions	0.3 g/L bovine serum albumen (BSA)
Dirty conditions	3.0 g/L BSA + 3.0 mL/L erythrocytes

Table 1. Interfering substances used to simulate clean and dirty conditions



The diluted test mixtures were added to plates containing indicator cells in cell culture medium. The cells were cultivated for the following number of days: influenza, 2; SARS and MERS, 3–5; and MVA, 6–8, then inspected microscopically for virus-induced changes in cell morphology. Virus titer was calculated from these observations using the Poisson formula. The virucidal activity was determined by the difference of the logarithmic titer of the virus control (mock treated cells) minus the logarithmic titer of the test virus ($\Delta \log_{10}$ TCID₅₀/ml). To demonstrate virucidal efficacy, disinfectant and antiseptic products are required to produce a log reduction in virus titer of at least 4.² As a validity control of the test system, formaldehyde was selected for inactivation of the reference virus.

Results



PVP-I Research Versus SARS

PVP-I efektif terhadap SARS-CoV yang menimbulkan infeksi SARS (Kariwa dkk, 2006),

MERS-CoV (Kirk-Bayley dkk, 2020),

Modified Vaccinia Virus Ankara (MVA) (Eggers dkk, 2015)

The new European test virus for enveloped virus (Eggers dkk, 2015), dan

Avian Influenza (Ito dkk, 2006).

PVP-I Research Versus SARS

Penggunaan PVP-I 0,23%
0,23% selama 2 menit
mampu menekan kuantitas
SARS-CoV virus hingga
kadar yang **tidak terdeteksi**
lagi.

PVP-I konsentrasi **1%** yang
digunakan selama **30 detik**,
mampu menurunkan
aktivitas virus MERS-CoV,
99,99%, (Eggers dkk, 2015).

PVP-I mampu menekan
TNF- α yang berperan
sebagai regulator inflamasi
pada banyak penyakit kronik
(König dkk, 1997).

Efektivitas PVP-I terhadap SARS-CoV

Aktivitas virusidal dalam 15 detik terhadap SARS-CoV	PVP-I Gargle & Mouthwash 1%	PVP-I Surgical Scrub 7.5%	PVP-I Skin Cleanser 4%
Faktor penurunan \log_{10}	> 4	> 4	> 4
Angka pemusnahan	>99.99%	>99.99%	>99.99%

Faktor penurunan $\log_{10} \geq 4$ (angka pemusnahan 99.99%) menunjukkan keampuhan virusidal yang efektif sesuai dengan Standard Eropa.²



Efektivitas PVP-I terhadap SARS-CoV

Reagent or treatment	Final PVP-I concentration, %	Virus titer after treatment, TCID ₅₀ /ml	
		60 s	120 s
Control	0	1.17 × 10 ⁶	n.d.
Isodine	1	95.1	u.d.
Isodine Gargle	0.47	190	u.d.
Isodine Scrub	1	u.d.	n.d.
Isodine Palm	0.25	u.d.	n.d.
Isodine Nodo Fresh	0.23	u.d.	n.d.
Ethanol (final 35%)	—	u.d.	n.d.

n.d. = Not done; u.d. = under the detectable level.


Studi invitro menunjukkan bahwa beberapa produk PVP-I efektif melawan SARS¹⁻³

1. Eggers. Infect Dis Ther (2015) 4:491–501
2. Kariwa H. Dermatology. 2006; 212 Suppl 1:119-23
3. Eggers M et al. Can oral disinfection with povidone iodine prevent viral respiratory infections? Abstract & Poster ASN226 IMRP Singapore 2015.

Efektivitas PVP-I terhadap SARS-CoV

- Evaluasi efektivitas penggunaan *in vitro* berbagai produk PVP-I terhadap SARS-CoV.¹
- Hasil: Aktivitas antiviral terhadap SARS-CoV tampak dalam 15 detik setelah paparan.

Aktivitas virusidal berbagai sediaan PVP-I terhadap SARS setelah 15 detik³



Log₁₀ reduction factor ≥4

*Log₁₀ reduction factor ≥ 4 (99.99% kill rate) demonstrate effective virucidal efficacy as stipulated in European Standard EN 14476:2013/A1:2014(2)

1. Eggers. Infect Dis Ther (2015) 4:491–501
2. EN14476:2013/A1:2014. Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements

Efektivitas PVP-I terhadap MERS-CoV

- PVP-I dapat berperan dalam membatasi penularan dan penyebaran MERS-CoV
- PVP-I Mouthwash dapat menurunkan jumlah virus dalam ronggal mulut dan orofaring

- Studi *in vitro* pada 3 formulasi PVP-I terhadap MERS-CoV.
- Hasil: Produk berbasis PVP-I menunjukkan aktivitas virusidal cepat terhadap virus MERS-CoV dalam 15 detik setelah paparan.

Ongoing journal review

NUS Duke Singapore, Mei 2020

Project title: Determining the efficacy of Povidone Iodine containing Betadine Products on the SARS-CoV-2 using in vitro viral kill time assays.

Methodology:

A total of 4 products (Antiseptic solution, Throat spray, Skin Cleanser and Mouthwash) were tested for viricidal activity on SARS-CoV-2 in my laboratory at Duke-NUS Medical School.

All procedures strictly adhered to Duke-NUS biosafety procedures and approved protocols.


Viricidal Activity Assay

The efficacy of 4 products; 10% Antiseptic Solution, 7.5% Skin Cleanser, 1% Gargle and Mouthwash and 0.45% Throat Spray against SARS-CoV-2 were tested in a suspension assay. Viricidal activity was performed taking into account the cytotoxicity of the product. Viricidal activity of all 4 products were tested in triplicate with a 30 second kill time.


Results and Conclusions:

The summarized results are attached.

The efficacy of four (4) Betadine PVP-I products; 10% Antiseptic Solution, 7.5% Skin Cleanser, 1% Gargle and Mouthwash and 0.45% Throat Spray against SARS-CoV-2 were tested in a suspension assay. In conclusion, all 4 tested Betadine products demonstrate viricidal activity (>4 log reduction of viral titre) against SARS-CoV-2 in 30 seconds.



PVP-I Mengendalikan Penyebaran Infeksi





SARS-CoV-2 rentan terhadap oksidasi sehingga mouthwash yang lebih tepat digunakan adalah hidrogen peroksida atau povidone iodine.¹

PVP-I memiliki aktivitas virusidal yang lebih tinggi dibandingkan antiseptik lainnya seperti chlorhexidine dan benzalkonium chloride.²

1. Peng X, et al. Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science (2020) 12:9.

2. Kirk-Bayley J, Challacombe S, Sunkaraneni VS, Combes J. The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. (March 28, 2020). Available at SSRN: <https://ssrn.com/abstract=3563092>

Povidone -iodine: Struktur Kimia




Ekuilibrium kimiawi Povidone-Iodine di dalam medium air²

- PVP-I merupakan suatu kompleks polimer sintetik *polyvinylpyrrolidone (povidone)* yang berikatan hidrogen dengan unsur iodium (I_3).³
- Di dalam larutan air, ekuilibrium kimiawi yang terbentuk membuat hanya sedikit iodine yang dilepas sebagai iodine bebas (I_2).⁴

¹ Schwarz W, et al. PVP-Jods. In Hierholzer G, Gortz G (eds): *PVP-Jod in der operativen Medizin*. Berlin: Springer. 1984:1–6. ² Fleischer W, et al. *Dermatology*. 1997;195(suppl 2):3–9; ³ Gottardi W. Iodine and iodine compounds. In: Block SS, ed. *Disinfection, Sterilization, and Preservation*; 4th ed. Philadelphia: Lea & Febiger. 1991:152–166 ⁴ Reimer K, et al. *Zent.bl Hyg Umweltmed*. 1997/98;200:423–434;


Mekanisme Kerja PVP-I

- Aktivitas mikrobisida dari *povidon-iodin* diakibatkan oleh pelepasan iodin bebas (I_2) dari kompleks *polyvinylpyrrolidone*.
- Saat *povidon-iodin* melepaskan iodin, ion *povidon-H* terbentuk, mengubah kompleks tersebut menjadi 'polielektrolit' yang berikatan dengan dinding sel mikroorganisme yang bermuatan negatif.
- Iodin kemudian mendenaturasi protein-protein yang sensitif pada membran, sehingga berakibat lisis dan kematian sel.




Mekanisme Kerja PVP-I

I₂ membunuh mikroorganisme dengan cara mengoksidasi struktur penting patogen (protein, DNA/RNA).



Protap Pemakaian
Obat Kumur PVP-I
yang benar



MEDICAL USE OF POVIDONE IODINE AGAINST COVID-19. WHY NOT?

Luis Mendoza, MD, PhD

Sr Medical Advisor

IQVIA

Czech Republic

Povidone-iodine (PVP-I) is an old antiseptic used in practice of medicine as a surgical scrub; for pre- and post-operative skin cleansing; for the treatment and prevention of infections in wounds, decubitus ulcers, cuts, and burns; in gynecology for vaginitis associated with candidal, trichomonal or mixed infections. For these purposes, PVP-I has been formulated at concentrations of 7.5–10.0% in solution, nasal and throat spray, surgical scrub, ointment, swab dosage forms, eye drop, and vaginal suppositories. The safety profile of PVP-I at such concentrations is well established and many available products in the market are over the counter. The most well-known brand for PVP-I is BETADINE.

PVP-I has been reported as a broad-spectrum microbicide with potency to inactivate bacteria, fungi, protozoans, and several viruses. After searching the medical database “PubMed” and entering the keywords: povidone-iodine and virus, I have found that there 101 scientific publications connect with PVP-I against viruses. The first publication about the efficacy of PVP-I was reported in 1975 where the PVP-I can reduce the titers of herpesvirus type 2 by 92% (1).

Recent in vitro studies have demonstrated virucidal activity of PVP-I against a wide range of

April 24, 2020

Draft version, awaiting journal acceptance and full peer review

The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers.

J Kirk-Bayley MRCP FRCA EDIC FFICM

Consultant Intensivist & Anaesthetist, Royal Surrey County Hospital

J Combes FDS FRCS (OMFS), Lt Col RAMC

Consultant Advisor (ARMY) in OMFS, Defence Medical Services

VS Sunkaraneni LLM FRCS (2009)


Consultant Rhinologist, Royal Surrey County Hospital

SJ Challacombe, PhD, FRCPath, FDSRCS, FMedSci, DSc(h.c), FKC

Martin Rushton Professor of Oral Medicine, King's College London

Abstract

In late 2019 a novel coronavirus, SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) appeared in Wuhan China, and on 11th March 2020 the World Health Organisation declared it to have developed pandemic status. In early SARS-CoV-2 infection, viral titres of greater than 10⁷/mL in saliva and nasal mucous can be found; minimisation of these titres should help to reduce cross infection. Povidone-iodine (PVP-I) disinfectant has better anti-viral activity than other antiseptics and has already been proven to be an extremely effective viricide *in vitro* against severe acute



Oral Oncology

journal homepage: www.elsevier.com/locate/oraloncology

Letter to the editor

Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as "Personal Protective Equipment" for frontline providers exposed in high-risk head and neck and skull base oncology care

Letter to the Editor

In response to the novel coronavirus SARS-CoV-2, healthcare systems have been challenged to allocate scarce resources while striving to achieve distribution justice to meet the critical needs of the communities they serve. Though there are ongoing randomized trials evaluating the utility of systemic therapies, post-convalescent serum, and vaccine development, these interventions are costly and time intensive. Alternative therapies and preventative measures are needed now, not only to accelerate the flattening of the epidemiologic curve, but also safeguard providers and patients as we re-evaluate tiered surgical responses and operational processes moving forward.

Early investigations in China have suggested that cancer patients harbored a higher risk of infection compared with the overall population and that infected cancer patients, particularly those who received chemotherapy or underwent surgery within a month of infection, were more susceptible to the need for critical care, respiratory support, and mortality [1]. In the viral hotspot of Wuhan, nosocomial spread was

centrations (e.g. 0.001%). A detailed review of its virucidal activity against a wide range of common viruses, including SARS-CoV and MERS-CoV coronaviruses, is beyond the scope of this article [6]. As a word of caution, *in vitro* studies using 10% and 5% PVP-I have demonstrated cilotoxicity on human respiratory cells [7]. However other investigations demonstrate continued virucidal effects of diluted PVP-I concentrations, without evidence of respiratory cilia toxicity, diminished olfactory function, or changes in mucosal appearance [8]. *In vitro* studies of 0.23% PVP-I mouthwash (1:30 dilution) can inactivate both SARS-CoV and MERSCoV following a 15-second exposure [6]. Though rare, prolonged use of topical 10% PVP-I solution (weeks-months) may increase the risk of iodine toxicity [9]. Allergy, contact sensitivity, and skin reactions are rare [10].

Here we present a novel intervention strategy utilizing topical applications of PVP-I to attenuate nosocomial transmission of COVID-19 surrounding head and neck and skull base oncology care. Given that frontline providers exposed to

10-15 ml PVP-I
di kumur ke
dalam rongga
mulut
selama 30 detik

30 detik
selanjutnya area
belakang
(kerongkongan)
kepala 45° ke
belakang
(bunyi rrrrrrrr)

Buang

Tidak makan,
minum, kumur
dengan air 30

5-6 x sehari
(tiap 4 jam)

Untuk pasien/ nakes yang asimptomatik atau berada di tempat yang high-risk: hingga 4 kali sehari.²

¹ Kirk-Bayley J, Challacombe S, Sunkaraneni VS, Combes J. The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. (March 28, 2020). Available at SSRN: <https://ssrn.com/abstract=3563092> or <http://dx.doi.org/10.2139/ssrn.3563092>

² Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as “Personal Protective Equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncology. Accepted 15 April 2020. <https://doi.org/10.1016/j.oraloncology.2020.104724>

SIAPA YANG PERLU BERKUMUR


Menjalani prosedur
berisiko tinggi

adanya sekresi dari nasal,
mukosa, oral, pharingeal
dan paru

Pasien (+) COVID 19

Berada di atau
berasal
dari area berisiko
tinggi COVID 19

Gunakan nasal dan oral (kumur dan gargle) dg PVP-I setiap 2-3 jam sekali sampai 4 kali/hari



Tenaga kesehatan yang **terlibat langsung** dalam penanganan pasien yang diduga/terlah terkonfirmasi **positif** terinfeksi SARSCoV-2

SIAPA YANG PERLU BERKUMUR


Terlibat langsung dalam prosedur penanganan pasien di **daerah berisiko tinggi COVID-19**

Sebelum dan setelah kontak dengan pasien

Mengalami **keterbatasan** APD(PPE)

Menangani prosedur **berisiko tinggi** pada pasien tak **bergejala**

Gunakan nasal dan oral (kumur dan gargle) dg PVP-I setiap 2-3 jam sekali sampai 4 kali/hari



Usulan masuk dalam Protap pasien OPD/PDP di Wisma Atlet

**LAPORAN PENGGUNAAN BETADINE® KUMUR DAN NASAL SPRAY
PADA PASIEN COVID-19 DI WISMA ATLET**

Nama Tenaga Kesehatan: No (kamar/bed):

Tanggal masuk

Nama	Alamat
Tgl lahir
Jenis kelamin	<input type="checkbox"/> Laki <input type="checkbox"/> Perempuan	Pekerjaan

Penyakit penyerta/komorbid
Riwayat terpapar COVID-19	<input type="checkbox"/> tidak tahu <input type="checkbox"/> berkontak pasien ODP/PDP <input type="checkbox"/> lainnya:
Gejala COVID-19	<input type="checkbox"/> s <input type="checkbox"/> b <input type="checkbox"/> g <input type="checkbox"/> ga

MONITORING PENGGUNAAN OBAT KUMUR DAN NASAL SPRAY BETADINE

Betadine Obat Kumur
*) berikan tanda "X" jika sudah melakukan kumur betadine.

	Kumur ke-1 Jam 06.00	Kumur ke-2 Jam 09.00	Kumur ke-3 Jam 12.00	Kumur ke-4 Jam 15.00	Kumur ke-5 Jam 18.00	Kumur ke-6 Jam 21.00
Hari ke-1						
Hari ke-2						
Hari ke-3						
Hari ke-4						
Hari ke-5						
Hari ke-6						
Hari ke-7						
Hari ke-8						
Hari ke-9						
Hari ke-10						
Hari ke-11						
Hari ke-12						
Hari ke-13						
Hari ke-14						

Penggunaan *Povidone Iodine* Jangka Panjang

- Tidak ada masalah keamanan yang baru yang dilaporkan pada penggunaan harian untuk:
 - Sariawan parah akibat radioterapi¹ - 6 minggu
 - Sariawan parah akibat kemoradiasi² - 9 minggu
 - Pencegahan gingivitis³ - 24 minggu
 - Stomatitis pada leukemia mielogenus akut⁴ - 1-3 tahun

Referensi: 1. Madan PD, et al. *J Cancer Res Ther.* 2008;4:3–8. 2. Rahn R, et al. *Dermatology.* 1997;195(Suppl 2):57–61. 3. Ader AW, et al. *J Clin Endocrinol Metab.* 1988;66:632–635. 4. Tsuzura Y, et al. *Gan To Kagaku Ryoho.* 1992;19:817–822.

Efek Samping Penggunaan dan Profil Keamanan PVP-I® Obat Kumur Antiseptik

- Penggunaan BETADINE® Obat Kumur Antiseptik tidak menunjukkan *staining* pada enamel gigi.
- Iritasi *idiosyncratic mucosal* dan reaksi hipersensitif.
- Absorbsi berlebihan dapat menyebabkan efek samping sistemik seperti metabolik asidosis, *hypernatremia* dan gangguan fungsi *renal*.
- Walaupun ada risiko *hyperthyroidism* atau *thyrotoxicosis* akibat pemaparan *Iodine*, hormon *thyroid* yang tidak normal bukan merupakan masalah utama.

Walaupun absorbsi sistemik *Iodine* dapat terjadi pada penggunaan jangka panjang, tetapi manifestasi kliniknya (gangguan fungsi *thyroid*) jarang terjadi.

Perhatikan *safety precaution* pada penggunaan BETADINE® Obat Kumur Antiseptik

Keamanan Povidone-Iodine Gargle

- Pengobatan dengan PVP-I Mouthwash & Gargle 1% tidak boleh melebihi 14 hari¹
 - Jika gejala tidak membaik setelah 14 hari, pasien harus menghubungi dokter.
- Namun, beberapa studi menggunakan Povidone-Iodine for Oral & Throat Care selama periode panjang tanpa ditemukannya masalah keamanan:

Meskipun tidak ada masalah keamanan baru yang dilaporkan terhadap penggunaan jangka panjang Povidone-Iodine Mouthwash & Gargle⁽²⁻⁵⁾, lakukan tindakan pencegahan keamanan.

(1) BETADINE® Gargle and Mouthwash 1% Prescribing Information (Cyprus SPC)package insert/leaflet, (2).Madan PD, et al. *J Cancer Res Ther.* 2008;4:3–8, (3).Rahn R, et al. *Dermatology.* 1997;195(Suppl 2):57–61, (4). Ader AW, et al. *J Clin Endocrinol Metab.* 1988;66:632–635, (5). Tsuzura Y, et al. *Gan To Kagaku Ryoho.* 1992;19:817–822


Keamanan Povidone-Iodine Gargle

Studi	Penggunaan Povidone-Iodine Mouthwash & Gargle
Madan PD, dkk. ²	PVP-I Mouthwash dua kali sehari selama 6 minggu pada manage radiotherapy-induced Oral Mucositis → PVP-I tidak menyebakan iritasi atau kerusakan mukosa mulut
Rahn R, dkk. ³	PVP-I Mouthwash 4 kali/hari selama 6 minggu pada radiochemotherapy-induced Oral Mucositis → PVP-I tidak menyebakan iritasi atau kerusakan mukosa mulut
Ader AW, <i>et al.</i> ⁴	Penilaian keamanan dan fungsi tiroid selama penggunaan PVP-I Mouthwash & Gargle setiap hari selama 6 bulan → Nilai marker tiroid tetap dalam kisaran normal → Tidak ada bukti berkembangnya disfungsi tiroid
Tsuzura Y, dkk. ⁵	PVP-I Gargle 8-10 kali/hari selama 1 hingga 3 tahun untuk pencegahan stomatitis pada pasien leukemia akut

Efek Cytotoxic Povidone-Iodine Lebih Rendah Dibanding Antiseptik lain pada Rongga Mulut

- Evaluation of the cytotoxicity of antiseptics used in oral care on human keratinocytes from gingival tissues¹**

Relative cytotoxicity of antiseptics at concentrations used in dental practice¹




PVP-I was less cytotoxic than other antiseptics used on mucous membranes in the oral cavity¹

Another *in vitro* study found that **PVP-I was less cytotoxic and better tolerated** than chlorhexidine, octenidine, and polyhexamethylene biguanide²

*Concentration of antiseptic that resulted in a 50% decrease in neutral red uptake when compared with the untreated control X dilution coefficient.

1. Tsutsui T, et al. *Toxicol In Vitro*. 1994;8(6):125-128.
2. Muller G, et al. *Dermatology*. 2006;212(Suppl1):91-93.


Summary



Oral hygiene penting dijaga saat wabah COVID-19, terkait reservoir berada di dalam mulut



Salah satu upaya untuk menjaga oral hygiene adalah dengan pembersihan rongga mulut secara mekanik dan obat kumur



Studi menunjukkan bahwa PVP-I gargle efektif mengatasi coronavirus MERS-CoV dan SARS-CoV1 dan 2 sehingga dapat menjadi pilihan dalam menekan penyebaran infeksi COVID-19

CEGAH RANTAI PENYEBARAN COVID-19 UNTUK INDONESIA SEHAT

**Terima Kasih
Semoga Bermanfaat**